1. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration with the Society of Thoracic Surgeons. Circulation [Internet]. 2019 Jul 9 [cited 2021 Aug 25];140(2). Available from: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000665
2. Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing G-J, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021 Aug 2;S0012-3692(21)01506-3.
3. Centers for Disease Control and Prevention. Ambulatory Health Care Data [Internet]. 2021 Dec. Available from: https://www.cdc.gov/nchs/ahcd/index.htm
4. Essien UR, Magnani JW, Chen N, Gellad WF, Fine MJ, Hernandez I. Race/ethnicity and sex-related differences in direct oral anticoagulant initiation in newly diagnosed atrial fibrillation: a retrospective study of Medicare data. J Natl Med Assoc. 2020;112(1):103–8.
5. Zhu J, Alexander GC, Nazarian S, Segal JB, Wu AW. Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010-2017. Pharmacotherapy. 2018;38(9):907–20.